Synthesis and efficacy analysis of multi-target TKI drug nintedanib

Yuxin Li

doi:10.1117/12.2669351

24 March 2023 Synthesis and efficacy analysis of multi-target TKI drug nintedanib

Yuxin Li

Proceedings Volume 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022); 126116I (2023) https://doi.org/10.1117/12.2669351
Event: International Conference on Biological Engineering and Medical Science (ICBioMed2022), 2022, Oxford, United Kingdom

Abstract

In the medical field, nintedanib (BIBF1120) belongs to a very potent small molecular buccal tyrosine kinase inhibitor (TKI), which plays an important role in the treatment of different diseases. For example, it can be used to treat idiopathic pulmonary fibrosis (IPF), lung cancer, and other interstitial lung diseases (ILD). Tripeptidase 1 (TPP1) was discovered to be a direct target for nintedanib using affinity-based protein profiling (AfBPP) technology, which might be a novel tyrosine kinase inhibition and nintedanib vary. After thorough clinical testing, the drug can be used to treat patients with a range of solid tumors and the crippling lung condition IPF. Although this drug is effective in treatment, it is very expensive. Therefore, it is necessary to study the synthesis route of nintedanib to reduce its price and make more patients able to buy the drug. Different synthetic routes for the nintedanib have been developed and greatly increased the yield of the nintedanib. As a result, the three ways that nintedanib is synthesized are analyzed in this article. The first is created via decarboxylated cyclization and acidic hydrogenation. The third employs the synthetic Eschen Moser coupling reaction path, whereas the second refines the first route. After comparing the three approaches, it can derive the best synthetic route of a drug and use it for the synthesis of the target drug. And the therapeutic effect of the target drug on the disease should not be further analyzed.

Citation Download Citation

Yuxin Li "Synthesis and efficacy analysis of multi-target TKI drug nintedanib", Proc. SPIE 12611, Second International Conference on Biological Engineering and Medical Science (ICBioMed 2022), 126116I (24 March 2023); https://doi.org/10.1117/12.2669351

ACCESS THE FULL ARTICLE

INSTITUTIONAL
Select your institution to access the SPIE Digital Library.

SELECT YOUR INSTITUTION

PERSONAL
Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.

PERSONAL SIGN IN

No SPIE Account? Create one

PURCHASE THIS CONTENT

SUBSCRIBE TO DIGITAL LIBRARY

50 downloads per 1-year subscription

Members: $195

Non-members: $335 ADD TO CART

25 downloads per 1 - year subscription

Members: $145

Non-members: $250 ADD TO CART

PURCHASE SINGLE ARTICLE

Includes PDF, HTML & Video, when available

Members: $17.00

Non-members: $21.00 ADD TO CART

PROCEEDINGS
8 PAGES

DOWNLOAD PAPER SAVE TO MY LIBRARY

GET CITATION

RIGHTS & PERMISSIONS

Get copyright permission Get copyright permission on Copyright Marketplace

KEYWORDS

Tumors

Proteins

Raw materials

Lung cancer

Pulmonary disorders

Cancer

Chemical species

Show All Keywords

Keywords/Phrases

Search In:

Publication Years